Lagos University Teaching Hospital

Running trials

• Recruiting

  Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer

  NCT06291064· Phase 2· University of Chicago· Source

• Recruiting

  A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease

  NCT06612268· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  Intensive Combination Approach to Rollback the HIV Epidemic in Nigerian Youth (iCARE) Plus Effectiveness/Implementation Hybrid Study

  NCT06880224· Northwestern University· Source

• Recruiting

  A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia

  NCT06609226· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  Tislelizumab in People With Colorectal Cancer

  NCT06529523· Phase 2· Memorial Sloan Kettering Cancer Center· Source

• Active, not recruiting

  A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)

  NCT05904886· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at Increased Risk for Primary Stroke

  NCT05953584· Phase 2· Forma Therapeutics, Inc.· Source

• Recruiting

  Reducing Mortality in Adults With Advanced HIV Disease (REVIVE)

  NCT05580666· Phase 3· Population Health Research Institute· Source

• Recruiting

  A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease

  NCT06198712· Phase 2· Forma Therapeutics, Inc.· Source

• Active, not recruiting

  A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)

  NCT05031780· Phase 2/3· Agios Pharmaceuticals, Inc.· Source

• Recruiting

  MicroRNA Profiles in Triple Negative Breast Cancer

  NCT04771871· Phase 2· University College Hospital, Ibadan· Source

• Recruiting

  Real World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in T2DM Patients - EASE Study

  NCT05164263· Phase 4· Getz Pharma· Source

• Active, not recruiting

  A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)

  NCT04624659· Phase 3· Forma Therapeutics, Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Sickle cell disease4 recruiting
• HIV2 recruiting
• Triple-negative breast cancer2 recruiting
• Colorectal cancer1 recruiting
• Stroke1 recruiting
• Thalassaemia1 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Completed

  Hydroxyurea and EPO in Sickle Cell Disease

  NCT05451940· Phase 1/2· Julia Xu· Source

• Terminated

  GBT021601-022: A Study of GBT021601 in Participants With Sickle Cell Disease (SCD)

  NCT05632354· Phase 2/3· Pfizer· Source

• Recruiting

  A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD

  NCT05431088· Phase 2/3· Pfizer· Source

• Completed

  Screening for Pregnancy Related Heart Failure in Nigeria

  NCT05438576· Mayo Clinic· Source

• Terminated

  Resolution of Sickle Cell Leg Ulcers With Voxelotor

  NCT05561140· Phase 3· Pfizer· Source

• Terminated

  A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease

  NCT05348915· Phase 3· Pfizer· Source

• Terminated

  A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises

  NCT04927247· Phase 3· Pfizer· Source

• Completed

  A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises

  NCT04935879· Phase 3· Pfizer· Source

• Completed

  Intensive Combination Approach to Rollback the Epidemic in Nigerian Adolescents: UH3 Phase

  NCT04950153· Northwestern University· Source

• Terminated

  Study to Evaluate the Effect of GBT440 on TCD in Pediatrics With Sickle Cell Disease

  NCT04218084· Phase 3· Pfizer· Source

• Completed

  Low Dose Aspirin for Preventing Intrauterine Growth Restriction and Preeclampsia in Sickle Cell Pregnancy (PIPSICKLE)

  NCT05253781· Phase 3· University of Lagos, Nigeria· Source

• Terminated

  Open-Label Extension of Voxelotor

  NCT04188509· Phase 3· Pfizer· Source

• Completed

  Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial

  NCT02699645· Phase 3· The George Institute· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Childhood cancers10 works · 0 trials